Multi-effect ceramide liposome as well as preparation method and application thereof

By preparing ceramide liposomes containing phosphatidylcholine and cholesterol, and combining them with octyldodecyl alcohol and sodium di(lauramide-glutamine)lysine, the problems of low solubility and poor transdermal absorption of ceramide NP were solved, achieving highly efficient and stable skin application and anti-aging effects.

CN118948666APending Publication Date: 2024-11-15SUZHOU MISIFU COSMETICS CO LTD
View PDF 0 Cites 6 Cited by

Patent Information

Application Number
CN202411083657.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In existing technologies, ceramide NP has low solubility, is prone to crystallization and precipitation, has poor transdermal absorption, low bioavailability, and is difficult to exist stably in high concentrations in cosmetics. Furthermore, the incomplete sealing of cyclodextrin encapsulation technology leads to the easy precipitation of active ingredients.

Method used

Ceramide liposomes, containing liposomes of phosphatidylcholine and cholesterol in a specific ratio, were prepared by combining octyldodecyl alcohol and sodium di(lauramide-glutamine)lysine as emulsifiers and homogenizing them through a gradient cooling and gradient pressure process. The resulting small-particle-size and stable ceramide liposomes were prepared.

Benefits of technology

It achieves high solubility and transparent dissolution of ceramide NP in water, improves transdermal absorption and bioavailability, and is stably present in cosmetics, with good skin feel and anti-aging effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004984536840000061
    Figure BDA0004984536840000061
  • Figure BDA0004984536840000101
    Figure BDA0004984536840000101
  • Figure BDA0004984536840000111
    Figure BDA0004984536840000111
Patent Text Reader

Abstract

The invention belongs to the field of cosmetics, particularly relates to the field of A61K8 / 68, and more particularly relates to a multifunctional ceramide liposome as well as a preparation method and application thereof. The ceramide liposome provided by the invention is prepared from the following components in parts by mass: 0.1 to 10 parts of functional substance, 1 to 10 parts of liposome, 5 to 20 parts of grease and 50 to 100 parts of matrix, wherein the liposome comprises phosphatidylcholine and cholesterol, the matrix comprises deionized water, an emulsifier, a humectant and a preservative, and the emulsifier comprises bis (lauramide glutamine) sodium lysine. The problems of dissolution and compatibility of ceramide are solved, the ceramide can be mutually dissolved with water in any ratio, the transparency after dissolution is high, the application is convenient, and the anti-wrinkle and repairing effects can be achieved when the addition amount of the ceramide with the mass concentration of 0.0125% is adopted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of cosmetics, in particular to the field of A61K8 / 68, and more specifically to a multi-functional ceramide liposome and a preparation method and application thereof. Background Art

[0002] The outermost layer of the epidermis is the stratum corneum, which is mainly composed of keratinocytes and lipids, similar to a "brick wall structure". The lipids, which act as "mortar", tightly connect the keratinocytes, which act as "bricks", to form a stratum corneum similar to a "brick wall", so that the skin barrier is normal, ensuring that neither moisture is lost nor external invasion is prevented. Among them, ceramide, as an important component of lipids, is very important for maintaining the skin barrier. Studies have shown that the reduction and abnormality of ceramide will bring many skin problems, such as damaged skin barrier, dehydrated and dry skin, sensitive skin, chronic skin inflammation, skin aging, atopic dermatitis, etc. In today's social life, there are many reasons for the decrease of ceramide in people's skin. For example, ceramide will gradually decrease with age, especially for people over 30 years old, the skin barrier and self-repair ability will be weakened due to the decrease of ceramide content; excessive skin cleansing or use of cleansing products with strong cleaning power, irregular work and rest, etc. will lead to different degrees of reduction of ceramide content, resulting in poor barrier ability, insufficient moisturizing, and easy sensitivity of the skin of the general consumers. In daily skin care, it becomes extremely important to supplement ceramide. There are many kinds of ceramides in our skin, among which ceramide NP has the highest content and is an indispensable ingredient for repairing the skin barrier and maintaining skin elasticity.

[0003] As reported in the prior art CN107920580A and CN115300410A, cyclodextrin encapsulation and liposome encapsulation technologies are commonly used in cosmetics to solve the problem of poor compatibility of raw materials. Cyclodextrin encapsulation technology utilizes vesicles with macromolecular structures to encapsulate active ingredients inside, but this technology is not completely closed and the active ingredients are easy to precipitate. When such products are added to pure water, ceramide is easy to precipitate, resulting in turbidity.

[0004] Liposomes can encapsulate active substances in bilayers to form a vesicle, which is often used in cosmetics to encapsulate, preserve and control the release of bioactive ingredients. Liposome encapsulation technology can solve the solubility problem of active substances. For example, substances with poor water solubility can be encapsulated by liposomes to make the entire encapsulation have better water solubility; it can also solve the bioavailability and improve the permeability of active substances on the skin; improve the stability of active substances through liposome encapsulation technology; and release active substances slowly through liposome encapsulation, thereby reducing irritation.

[0005] Then, in actual research and development, it was found that the formulation development process of ceramide NP and the process of using cosmetics with added ceramide also have the following application pain points:

[0006] 1. Ceramide NP is a highly crystalline substance with low solubility. The formulated product is prone to crystallization during storage;

[0007] 2. Poor transdermal absorption and low skin retention lead to low bioavailability;

[0008] 3. The amount added in cosmetics is low, and it is difficult to stably exist in the formula at a high content;

[0009] To address the pain points of the above applications, we hope to develop a ceramide NP nanoliposome material that has high solubility in water, is transparent after dissolution, has a good skin feel, and has a high transdermal absorption rate. Summary of the invention

[0010] In view of the problems in the prior art, the present invention provides a ceramide liposome, which comprises, by weight: 0.1-10 parts of an effective substance, 1-10 parts of a liposome, 5-20 parts of oil, and 50-100 parts of a matrix.

[0011] Preferably, the functional substance includes one or more of ceramide NP, ceramide NH, ceramide AH, ceramide NDS, ceramide AS, ceramide AP, ceramide NS, ceramide EOS, ceramide EOH, ceramide ADS, ceramide EOP, and ceramide EODs.

[0012] Further preferably, the functional substance includes ceramide NP and / or ceramide AP.

[0013] More preferably, the effective substance is ceramide NP.

[0014] Preferably, the liposome comprises one or more of lecithin, hydrogenated lecithin, cholesterol, and phosphatidylcholine.

[0015] Further preferably, the liposomes comprise phosphatidylcholine and cholesterol, and the mass ratio of phosphatidylcholine to cholesterol is (5-20):1.

[0016] Phosphatidylcholine is an indispensable substance for human cells. If it is lacking, the regeneration ability of skin cells will be reduced, resulting in rough skin, wrinkles, etc. At the same time, phosphatidylcholine has moisturizing and antioxidant effects. Adding this ingredient to cosmetics can guarantee the vitality of skin regeneration, and this ingredient has good hydrophilicity and lipophilicity, which will increase the skin luster after use; cholesterol is a natural component in the stratum corneum of the skin, which can form a sebum membrane with components such as fatty acids, and has the effects of moisturizing, lubricating and preventing water evaporation. It also has the effects of anti-oxidation, anti-wrinkle, and inhibiting melanin production. The inventor unexpectedly found that when the mass ratio of phosphatidylcholine and cholesterol is (5-20): 1 and compounded as liposomes, cholesterol is an elasticity regulator of the liposome membrane, which can regulate the stability of the membrane and can effectively and stably encapsulate ceramide NP.

[0017] Preferably, the oil comprises one or more of octyl dodecanol, isododecane and isohexadecane.

[0018] Further preferably, the oil comprises octyl dodecanol.

[0019] The preferred oil in the present invention is octyldodecanol, which has a skin permeation promoting effect, can promote the skin permeation absorption of ceramide NP, and increase the skin permeation speed. At the same time, the compound of octyldodecanol and cholesterol also has an emulsifying and softening effect, providing additional fat for the skin, reducing water evaporation, and making the skin soft and smooth.

[0020] Preferably, the matrix includes deionized water, an emulsifier, a moisturizer, and a preservative.

[0021] Further preferably, the matrix comprises, by weight, 40-50 parts of deionized water, 20-40 parts of moisturizer, 0.1-1 part of emulsifier, and 0.1-1 part of preservative.

[0022] Preferably, the moisturizing agent comprises polyols and / or sugar compounds.

[0023] As the polyol in the moisturizer, a C2-C30 polyol is preferred, which may be a polyol containing an ether bond in the molecule or a polyol without an ether bond. Preferably, the C2-C30 polyol has a water-soluble C2-C30 saturated aliphatic alcohol with 2 to 6 hydroxyl groups. For example, such polyols include: diols such as ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, polyethylene glycol, propylene glycol, 1,3-propylene glycol, dipropylene glycol, polypropylene glycol, 1,3-butylene glycol, 1,2-butylene glycol, 1,4-butylene glycol, 2,3-butylene glycol, 1,2-pentanediol, etc.; triols such as glycerol, trimethylolpropane, etc.; tetraols such as diglycerol, erythritol, pentaerythritol, etc.; pentaols such as xylitol, triglycerol, etc.; hexaols such as sorbitol, mannitol, etc.; and their polymers such as diglycerol, triglycerol, tetraglycerol, polyglycerol.

[0024] Preferably, the carbohydrate compound includes one or more of sorbitol, acetyl glucosamine, trehalose, sucrose, maltitol, pullulan, sodium hyaluronate, hydrolyzed sodium hyaluronate, mushroom glucan, methylsilanol mannuronate, methyl gluceth-20, anhydroxylitol, and xylitol glucoside.

[0025] Preferably, the emulsifier includes one or more of anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

[0026] Further preferably, the emulsifier is an amphoteric surfactant; as an practicable case, the amphoteric surfactant includes one of sodium dodecylaminopropionate, dodecylethoxysulfobetaine, dodecyldimethylhydroxypropylsulfobetaine, lauroylpropylamine oxide, and sodium di(lauroyl glutamine) lysine.

[0027] More preferably, the emulsifier is sodium di(laurylamide glutamine) lysine.

[0028] Sodium di(laurylamide glutamine) lysine has the characteristics of low toxicity, high permeability and high skin compatibility. It has great similarity with the molecular structure of ceramide, but the hydrophilic-lipophilic balance between the two molecules is very different. Sodium di(laurylamide glutamine) lysine forms a nested structure by interacting with ceramide molecules, disrupting the orderly arrangement of ceramide molecules, ensuring the amorphous state of ceramide, and hindering the crystallization process. Sodium di(laurylamide glutamine) lysine itself is charged, which has a good penetration-promoting effect.

[0029] The present invention does not further limit the preservatives, and any substance that can inhibit the growth and reproduction of microorganisms in cosmetics can be used, including but not limited to phenoxyethanol, p-hydroxyacetophenone, ethylhexylglycerin, and 1,2-hexanediol; p-hydroxyacetophenone and 1,2-hexanediol are preferred in the present invention, and the mass ratio is (1-2):1.

[0030] The second aspect of the present invention provides a method for preparing ceramide liposomes, comprising the following steps:

[0031] S1. Weigh the liposomes, functional substances and oils according to the proportion and stir them at 200-400 rpm in a water bath at 70-95°C to completely dissolve the raw materials to obtain phase A;

[0032] S2. Deionized water, moisturizer and emulsifier are weighed in proportion, preheated in a water bath at 70-95°C for 30 min, and stirred at 200-350 rpm for 5 min until uniform to obtain phase B. Then, phase A is injected into phase B at a rate of 5 g / min under homogenization conditions at 1000-2000 rpm, and hydration is continued for 20 min. Then, the temperature is lowered to 60-70°C to obtain phase AB.

[0033] S3, homogenizing the obtained AB phase using a microfluidizer, the homogenization cycle number is 3 times, the first homogenization pressure is set to 20000-25000psi, and the discharge temperature of the first homogenization is controlled to be 50-60°C; the second homogenization pressure is set to 15000-20000psi, and the discharge temperature of the second homogenization is controlled to be 40-50°C; the third homogenization pressure is set to 10000-15000psi, and the discharge temperature of the third homogenization is controlled to be 15-25°C, which is colostrum;

[0034] S4. After weighing the preservatives according to the proportion, stir at 200-300 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 200-400 rpm for 10 minutes until uniform, and then collect the material.

[0035] A third aspect of the present invention provides an application of ceramide liposomes in the field of cosmetic production, wherein the cosmetics include but are not limited to emulsions, creams, essences and other dosage forms of cosmetics.

[0036] Beneficial Effects

[0037] (1) The ceramide liposome provided by the present invention solves the problem of ceramide dissolution and compatibility, can be miscible with water in any ratio, has high transparency after dissolution, and is easy to use.

[0038] (2) The ceramide liposomes provided in the present invention have a small average particle size and can be retained at a high concentration in the target part of the skin, thereby improving the bioavailability of ceramide. At the same time, they are very stable to changes in pH, shear and temperature, and can bring skin care products an extremely delicate and silky skin feel that is refreshing and non-sticky.

[0039] (3) The preferred emulsifier in the present invention is the amphoteric surfactant di(laurylamide glutamine) sodium lysine, which can effectively inhibit the crystallization of ceramide molecules and improve the transdermal absorption rate of ceramide. Compared with cyclodextrin, it has a better encapsulation effect, and ceramide is not easy to precipitate in the system.

[0040] (4) In the S3 step of preparing ceramide liposomes of the present invention, gradient cooling and gradient pressure are used when homogenizing for 3 cycles. Gradient cooling can greatly retain the activity of the active substance. Controlling the third homogenization temperature at 10-20°C allows the product to cool instantly, ensuring the liposome structure and reducing PDI (polymer dispersibility index). Gradient pressure can also better control the size and uniformity of the liposomes and achieve better sample stability. Due to the high transdermal retention and small and stable molecular weight, the inventors found that the ceramide liposomes provided by the present invention can achieve good effects at a lower addition amount relative to unencapsulated ceramide; in addition to having good repair effects, ceramide liposomes also have good anti-aging effects.

[0041] (5) When the encapsulated ceramide of the present invention was added at a mass percentage of 0.0125%, it was found that the content of type I collagen (CollagenI) was significantly increased, with an increase rate of 61.01%, the content of matrix metalloproteinase 1 (MMP-1) was significantly decreased, with a downregulation rate of 13.21%, and the expression level of NQO-1 gene was significantly increased, with an upregulation rate of 72.73%. This indicates that ceramide liposomes at this concentration can increase the content of type I collagen (CollagenI), downregulate the content of matrix metalloproteinase 1 (MMP-1), and upregulate the expression level of NQO-1 gene, and have anti-wrinkle effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 For CN0308( Figure 1 Left) and CN0314( Figure 1 Right) Product appearance comparison picture.

[0043] Figure 2 For CN0308( Figure 2 Left) and CN0314( Figure 2 Right) Comparison of the appearance of 10% aqueous dispersion products.

[0044] Figure 3 This is the transmittance test result diagram.

[0045] Figure 4 This is a diagram of the transdermal penetration test results of Example 1.

[0046] Figure 5 This is a curve chart of honey restoring cell vitality.

[0047] Figure 6 This is a morphological diagram of honey recovery cells.

[0048] Figure 7 This is a bar graph of NQO-1 gene test results.

[0049] Figure 8 It is a bar graph of the Collagen Ι content detection results.

[0050] Fig. 9 It is a bar graph of the MMP-1 content detection results.

[0051] Fig.10 This is a graph showing the results of the FLG test.

[0052] Fig.11 It is a bar graph of the relative integrated optical density (IOD) values ​​of FLG.

[0053] Fig.12 This is the result of the loricrin (LOR) test.

[0054] Fig.13 This is the LOR relative integrated optical density (IOD) test result diagram.

[0055] Fig.14 This is the test result of tight junction protein 1 (Claudin-1).

[0056] Fig.15 It is a bar graph of the relative integrated optical density (IOD) values ​​of Claudin-1. DETAILED DESCRIPTION

[0057] Examples 1-3 and Comparative Examples 1-4

[0058] A ceramide liposome, specific raw material components and weight fractions are shown in Table 1.

[0059] Table 1

[0060]

[0061] Note: The above raw materials are commercially available unless otherwise specified.

[0062] The preparation method of the ceramide liposome described in Example 1 is:

[0063] S1. Weigh ceramide NP, phosphatidylcholine, cholesterol, and octyldodecanol in proportion and stir at 300 rpm in a water bath at 85°C to completely dissolve the raw materials to obtain phase A.

[0064] S2. Deionized water, butylene glycol, glycerol, and sodium di(laurylamide glutamine) lysine were weighed in proportion, preheated in a water bath at 80°C for 30 min, and stirred at 300 rpm for 5 min until uniform to obtain phase B. Phase A was then injected into phase B at a rate of 5 g / min under homogenization conditions at 1500 rpm, and hydration was continued for 20 min. The mixture was then cooled to 65°C to obtain phase AB.

[0065] S3, homogenizing the obtained AB phase using a microfluidizer, the number of homogenization cycles is 3, the first homogenization pressure is set to 24000psi, and the discharge temperature of the first homogenization is controlled to be 55°C; the second homogenization pressure is set to 18000psi, and the discharge temperature of the second homogenization is controlled to be 45°C; the third homogenization pressure is set to 12000psi, and the discharge temperature of the third homogenization is controlled to be 20°C, which is colostrum;

[0066] S4. After weighing the preservatives according to the proportion, stir at 240 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 300 rpm for 10 minutes until uniform, and then collect the material; record it as Honey Fuyuan, and the sample batch number is CN0308.

[0067] The ceramide liposomes obtained in this example are used in the field of cosmetic production, specifically in the preparation of creams.

[0068] The preparation method of the ceramide liposome described in Example 2 is:

[0069] S1: Weigh ceramide NP, phosphatidylcholine, cholesterol, and octyldodecanol in proportion and stir at 200 rpm in a 70°C water bath to completely dissolve the raw materials to obtain phase A;

[0070] S2: Deionized water, butylene glycol, glycerol, and sodium di(laurylamide glutamine) lysine were weighed in proportion, preheated in a 70°C water bath for 30 min, and stirred at 300 rpm for 5 min until uniform to obtain phase B. Phase A was then injected into phase B at a rate of 5 g / min under a homogenizing condition of 1000 rpm.

[0071] The hydration was continued for 20 min, and then the temperature was lowered to 60 °C to obtain the AB phase;

[0072] S3: The obtained AB phase is homogenized using a microfluidizer, and the number of homogenization cycles is 3. The first homogenization pressure is set to 20,000 psi, and the discharge temperature of the first homogenization is controlled to be 50° C.; the second homogenization pressure is set to 15,000 psi, and the discharge temperature of the second homogenization is controlled to be 40° C.; the third homogenization pressure is set to 12,000 psi, and the discharge temperature of the third homogenization is controlled to be 15° C., which is colostrum;

[0073] S4: After weighing the preservatives according to the proportion, stir at 200 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 200 rpm for 10 minutes until uniform, and then collect the material.

[0074] The preparation method of the ceramide liposome described in Example 3 is:

[0075] S1: Weigh ceramide NP, phosphatidylcholine, cholesterol, and octyldodecanol in proportion and stir at 400 rpm in a 95°C water bath to completely dissolve the raw materials to obtain phase A;

[0076] S2: Deionized water, butylene glycol, glycerol, and sodium di(laurylamide glutamine) lysine were weighed in proportion, preheated in a 95°C water bath for 30 min, and stirred at 350 rpm for 5 min until uniform to obtain phase B. Phase A was then injected into phase B at a rate of 5 g / min under a homogenizing condition of 2000 rpm.

[0077] The hydration was continued for 20 min, and then the temperature was lowered to 70 °C to obtain the AB phase;

[0078] S3: The obtained AB phase is homogenized by a microfluidizer for 3 homogenization cycles. The first homogenization pressure is set to 25000 psi, and the discharge temperature of the first homogenization is controlled to be 60°C; the second homogenization pressure is set to 20000 psi, and the discharge temperature of the second homogenization is controlled to be 50°C; the third homogenization pressure is set to 15000 psi, and the discharge temperature of the third homogenization is controlled to be 25°C, which is colostrum;

[0079] S4: After weighing the preservatives according to the proportion, stir at 300 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 400 rpm for 10 minutes until uniform, and then collect the material.

[0080] The preparation method of the ceramide liposome described in Comparative Example 1 is:

[0081] S1. Weigh ceramide NP, phosphatidylcholine, cholesterol, and octyldodecanol in proportion and stir at 300 rpm in a water bath at 85°C to completely dissolve the raw materials to obtain phase A.

[0082] S2. Deionized water, butanediol and glycerol were weighed in proportion and preheated in a water bath at 80°C for 30 min. The mixture was stirred at 300 rpm for 5 min until uniform to obtain phase B. Phase A was then injected into phase B at a rate of 5 g / min at 1500 rpm for hydration for 20 min. The mixture was then cooled to 65°C to obtain phase AB.

[0083] S3, homogenizing the obtained AB phase using a microfluidizer, the number of homogenization cycles is 3, the first homogenization pressure is set to 24000psi, and the discharge temperature of the first homogenization is controlled to be 55°C; the second homogenization pressure is set to 18000psi, and the discharge temperature of the second homogenization is controlled to be 45°C; the third homogenization pressure is set to 12000psi, and the discharge temperature of the third homogenization is controlled to be 20°C, which is colostrum;

[0084] S4. After weighing the preservatives according to the proportion, stir at 240 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 300 rpm for 10 minutes until uniform, and then collect the material; the sample batch number is CN0314.

[0085] The preparation method of the ceramide liposome described in Comparative Example 2 is:

[0086] S1. Weigh ceramide NP, phosphatidylcholine, cholesterol, and octyldodecanol in proportion and stir at 300 rpm in a water bath at 85°C to completely dissolve the raw materials to obtain phase A.

[0087] S2. Deionized water, butylene glycol, glycerol, and sodium di(laurylamide glutamine) lysine were weighed in proportion, preheated in a water bath at 80°C for 30 min, and stirred at 300 rpm for 5 min until uniform to obtain phase B. Phase A was then injected into phase B at a rate of 5 g / min under homogenization conditions at 1500 rpm, and hydration was continued for 20 min. The mixture was then cooled to 65°C to obtain phase AB.

[0088] S3, homogenizing the obtained AB phase using a microfluidizer, with the homogenization cycle number being 1, the homogenization pressure being 24000 psi, and the discharge temperature being 45° C., to obtain colostrum;

[0089] S4. After weighing the preservatives according to the proportion, stir at 240 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 300 rpm for 10 minutes until uniform, and then collect the material.

[0090] The preparation method of the ceramide liposome described in Comparative Example 3 is:

[0091] S1. Weigh ceramide NP, phosphatidylcholine, cholesterol, and octyldodecanol in proportion and stir at 300 rpm in a water bath at 85°C to completely dissolve the raw materials to obtain phase A.

[0092] S2. Deionized water, butylene glycol, glycerol, and sodium di(laurylamide glutamine) lysine were weighed in proportion, preheated in a water bath at 80°C for 30 min, and stirred at 300 rpm for 5 min until uniform to obtain phase B. Phase A was then injected into phase B at a rate of 5 g / min under homogenization conditions at 1500 rpm, and hydration was continued for 20 min. The mixture was then cooled to 65°C to obtain phase AB.

[0093] S3, homogenizing the obtained AB phase using a microfluidizer, the homogenization cycle number is 3 times, the first homogenization pressure is set to 24000psi, and the discharge temperature of the first homogenization is controlled to be 45°C; the second homogenization pressure is set to 18000psi, and the discharge temperature of the second homogenization is controlled to be 45°C; the third homogenization pressure is set to 12000psi, and the discharge temperature of the third homogenization is controlled to be 45°C, which is colostrum;

[0094] S4. After weighing the preservatives according to the proportion, stir at 240 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 300 rpm for 10 minutes until uniform, and then collect the material.

[0095] The preparation method of the ceramide liposome described in Comparative Example 4 is:

[0096] S1. Weigh ceramide NP, phosphatidylcholine, cholesterol, and octyldodecanol in proportion and stir at 300 rpm in a water bath at 85°C to completely dissolve the raw materials to obtain phase A.

[0097] S2. Deionized water, butylene glycol, glycerol, and sodium di(laurylamide glutamine) lysine were weighed in proportion, preheated in a water bath at 80°C for 30 min, and stirred at 300 rpm for 5 min until uniform to obtain phase B. Phase A was then injected into phase B at a rate of 5 g / min under homogenization conditions at 1500 rpm, and hydration was continued for 20 min. The mixture was then cooled to 65°C to obtain phase AB.

[0098] S3, homogenizing the obtained AB phase using a microfluidizer, the homogenization cycle number is 3 times, the first homogenization pressure is set to 10000psi, and the discharge temperature of the first homogenization is controlled to be 55°C; the second homogenization pressure is set to 10000psi, and the discharge temperature of the second homogenization is controlled to be 45°C; the third homogenization pressure is set to 10000psi, and the discharge temperature of the third homogenization is controlled to be 20°C, which is colostrum;

[0099] S4. After weighing the preservatives according to the proportion, stir at 240 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 300 rpm for 10 minutes until uniform, and then collect the material.

[0100] Comparative Example 5

[0101] A ceramide liposome, wherein the raw materials for preparing the ceramide liposome are as follows: 37 parts of glycerol, 45 parts of deionized water, 8 parts of octyldodecanol, 8 parts of soybean lecithin, 3 parts of ceramide NP, 0.5 parts of cholesterol, 0.5 parts of p-hydroxyacetophenone, 0.5 parts of 1,2-hexanediol, and 0.5 parts of an emulsifier, sodium stearoyl glutamate.

[0102] The preparation method of ceramide liposomes described in this example is:

[0103] S1. Weigh ceramide NP, soybean lecithin, cholesterol, and octyldodecanol in proportion and stir at 300 rpm in a water bath at 85° C. to completely dissolve the raw materials to obtain phase A.

[0104] S2. Deionized water, butylene glycol and sodium stearoyl glutamate were weighed in proportion, preheated in a water bath at 80°C for 30 min, and stirred at 300 rpm for 5 min until uniform to obtain phase B. Then, phase A was injected into phase B at a rate of 5 g / min under a homogenizing condition of 1500 rpm, and hydration was continued for 20 min. Then, the temperature was lowered to 65°C to obtain phase AB.

[0105] S3, homogenizing the obtained AB phase using a microfluidizer, the number of homogenization cycles is 3, the first homogenization pressure is set to 24000psi, and the discharge temperature of the first homogenization is controlled to be 55°C; the second homogenization pressure is set to 18000psi, and the discharge temperature of the second homogenization is controlled to be 45°C; the third homogenization pressure is set to 12000psi, and the discharge temperature of the third homogenization is controlled to be 20°C, which is colostrum;

[0106] S4. After weighing the preservatives according to the proportion, stir at 240 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 300 rpm for 10 minutes until uniform, and then collect the material.

[0107] Performance Testing

[0108] Test 1: Particle size, dispersion, and appearance of samples of various embodiments and comparative examples

[0109] The average particle size (1% mass concentration aqueous dispersion), dispersion (1% mass concentration aqueous dispersion), and appearance of the ceramide liposome samples of Examples 1-3 and Comparative Examples 1-5 were observed. The test results are shown in Table 2.

[0110] Table 2

[0111]

[0112]

[0113] After the samples of Examples 1-3 and Comparative Examples 1-5 were prepared, they were placed at room temperature at 25°C for 24 hours, the appearance of the samples was observed, and the particle size and dispersion were measured. The samples of Examples 1-3 were all colorless transparent liquids, while the samples of Comparative Examples 1-5 had poor transparency and were colorless translucent or light yellow translucent liquids.

[0114] The dispersities of Examples 1-3 and Comparative Example 5 are less than 0.500, and the average particle size is small, ranging from 20 to 55 nm, while the dispersities of Comparative Examples 1-4 are all greater than 0.500, and the average particle size is large, ranging from 60 to 120 nm. This indicates that the sizes of the ceramide NP liposomes in the samples of Comparative Examples 1-4 are not uniform, and theoretically there may be a problem of poor stability.

[0115] Test 2: Stability test

[0116] The samples of Examples 1-3 and Comparative Examples 1-5 were stored for 30 days under 4 different conditions, and the stability was evaluated based on product appearance, particle size (1% concentration dispersed liquid), dispersion (1% concentration dispersed liquid), and pH change. The test results are detailed in Table 3.

[0117] Table 3

[0118]

[0119] After being stored for 30 days, the samples of Examples 1-3 were stable at room temperature, 4°C and -20°C, and the average particle size, pH and appearance were basically unchanged at 4°C, -20°C and room temperature, and were evaluated as stable. At a high temperature of 45°C, the pH of the samples did not change, the average particle size first increased and then decreased, and the transparency of the appearance decreased slightly, indicating that high temperature had a slight effect on its stability.

[0120] After storage for 30 days, the sample of Comparative Example 1 was unstable at 45°C and room temperature, the particle size increased significantly, and the transparency decreased significantly. It was basically stable at 4°C and -20°C. Comparative Examples 2-5 were unstable under all conditions, and the transparency decreased significantly, especially at room temperature and high temperature, the appearance became more turbid and opaque.

[0121] Test 3: Comparison between Example 1 and Comparative Example 1

[0122] The samples of Example 1 and Comparative Example 1 were tested for particle size. A 1% aqueous dispersion was used for the test. The test was performed by a nanoparticle size analyzer at room temperature of 25°C. The test results showed that the particle size of the sample of Example 1 (CN0308) was 82.90nm and the PDI was 0.503; the particle size of the sample of Comparative Example 1 (CN0314) was 20.20nm and the PDI was 0.241. The results show that the absence of sodium di(laurylamide glutamine) lysine significantly increases the particle size of the product, indicating that the product appearance is affected; the increase in PDI indicates that the particle size uniformity of the product decreases.

[0123] like Figure 1 As shown, CN0308( Figure 1 Left) and CN0314( Figure 1 Right) Product appearance comparison chart. It can be seen from the chart that CN0314 is a clear and transparent liquid, while the transparency of CN0308 is reduced.

[0124] like Figure 2 As shown, it is CN0308( Figure 2 Left) and CN0314( Figure 2 Right) Product appearance comparison chart. It can be seen from the chart that the 10% aqueous dispersion of CN0314 is a clear transparent liquid with light blue opalescence, while the 10% aqueous dispersion of CN0308 is a light blue translucent liquid with reduced transparency.

[0125] It can be seen from Example 1 and Comparative Example 1 that the addition of sodium di(laurylamide glutamine) lysine to the ceramide NP encapsulation system can reduce the transparency of the system and form a more transparent liquid, in which the average particle size of the encapsulated ceramide liposomes is smaller and the uniformity is better, thereby having better stability.

[0126] Test 4: Light transmittance test

[0127] The transmittance of Example 1 and commercially available samples 1 and 2 was tested. The transmittance of different test samples at different concentrations was tested by spectrophotometry. During the test, the wavelength of the spectrophotometer was set to 600nm, and pure water was used as a reference, and the transmittance of pure water was 100%.

[0128] Experimental group: ceramide liposomes of Example 1.

[0129] Control group: control substance 1 (ceramide 3 liposomes, purchased from Zhina Technology); control substance 2 (ceramide precision biomimetic liposomes, purchased from Suzhou Nakang Biological).

[0130] The concentrations of the samples in the experimental group and the control group were set as follows: 1.0%, 2.5%, 5.0%, 7.5%, 10.0%, respectively. For detailed test data, see Figure 3 .

[0131] Depend on Figure 3 The results show that the transmittance of ceramide liposome honey recovery in Example 1 at all concentrations is much higher than that of reference product 2. When the sample mass concentration is lower than 5%, the transmittance of reference product 1 is equivalent to that of honey recovery. When the sample mass concentration is higher than 5%, the transmittance of honey recovery is better than that of reference product 1. The transmittance of 10% honey recovery is still close to 100%, indicating that honey recovery has good light transmittance and high transparency.

[0132] Test 5. Transdermal penetration experiment of Example 1

[0133] 1. For the transdermal permeation experiment, Bama pig skin was selected as the test model and Franz cell diffusion pool system was used as the test system.

[0134] 2. Preparation of control group and treatment group:

[0135] 1) Preparation of control group samples: unencapsulated ceramide (ceramide NP-butylene glycol solution with a mass concentration of 1.2%) sample was mixed with an essence base to obtain an unencapsulated ceramide control group essence sample.

[0136] 2) Preparation of treatment group samples: The encapsulated ceramide sample (Honey Fuyuan, in which the mass concentration of ceramide NP is 1.2%) is mixed with the essence matrix to obtain an essence sample of the non-encapsulated ceramide control group.

[0137] 3) Essence base formula: 3% propylene glycol, 3% glycerin, 0.8% thickener SIMULGEL FL (hydroxyethyl acrylate & sodium dimethyl acrylate taurate copolymer & isohexadecane & polysorbate 60), and the rest is water.

[0138] 3. Transdermal absorption test steps

[0139] 1) Assembly and fixation of the test model: The Bama pig skin membrane is fixed between the diffusion chamber and the receiving chamber of the Franz cell diffusion tank, with the stratum corneum of the Bama pig skin membrane facing the diffusion chamber and the dermis facing the receiving chamber. After the Bama pig skin is fixed, 8 mL of receiving solution is added to the receiving chamber to make the Bama pig skin in close contact with the receiving solution.

[0140] 2) The Franz diffusion cell was fixed in the transdermal diffusion instrument, the temperature was set to 32°C, and the speed of the magnetic stirring rotor was set to 600 rpm.

[0141] 3) Sampling: After the water bath temperature of the diffusion instrument is constant, the sample is loaded. The sample addition amount is 0.1 g. The sample is added to the surface of the Bama pig skin and spread evenly.

[0142] 4) After 12 hours of the experiment, the stratum corneum was peeled off by tape stripping. The stratum corneum was repeatedly taped 20 times and then dissolved with methanol to a constant volume.

[0143] 5) Quantitative analysis by LC-MS.

[0144] 4. Statistics and analysis

[0145] Q=(Cn*V) / A;where:

[0146] Q: Retention amount, refers to the retention amount of ceramide in the stratum corneum;

[0147] Cn: stratum corneum stripping concentration;

[0148] V: extraction volume;

[0149] A: Spread skin area.

[0150] Transdermal permeation experimental results of Example 1: The 12h transdermal permeation experimental data of ceramide NP and encapsulated ceramide NP are shown in Table 4.

[0151] Table 4

[0152] Experimental Group <![CDATA[Cutaneous retention amount (μg / cm 2 )]]> Control group (not encapsulated with ceramide) 0.59 Treatment group (encapsulated ceramide) 2.23

[0153] After 12 hours of penetration, the stratum corneum retention of ceramide NP in the treatment group was 2.23 μg / cm 2 , which is 3.8 times the retention amount of ceramide NPs in the control group.

[0154] Test 6: Zebrafish embryo tail fin repair promotion test

[0155] The fish embryo culture medium was prepared by weighing 2940 mg of anhydrous calcium chloride, 1233 mg of magnesium sulfate heptahydrate, 630 mg of sodium bicarbonate, and 55 mg of potassium chloride and dissolving them in 10 L of water. The pH value was 6.5-8.5, and all chemicals were of analytical grade.

[0156] Water-soluble cosmetic raw materials / products: directly dissolve the test substance in fish embryo culture medium to prepare the test solution.

[0157] The test requires setting up a blank control group (normal zebrafish embryos without tail cut in fish embryo culture medium), a model control group (fish embryo culture medium), a positive control group (Rehmannia glutinosa extract) and a test substance group (test substance).

[0158] Positive control group: weigh 0.5g of Rehmannia glutinosa extract and dissolve it in 5mL of water to prepare the storage solution, refrigerate, and it is valid within 30 days; the working solution is to dilute the storage solution 100 times with fish embryo culture medium and prepare it fresh before use.

[0159] Sample treatment group 1: the ceramide liposomes of Example 1 were prepared into embryo culture medium with a mass concentration of 3%.

[0160] Sample treatment group 2: The ceramide liposomes of Example 1 were prepared into embryo culture medium with a mass concentration of 1%.

[0161] The test results are detailed in Figure 4 and Table 5.

[0162] Table 5

[0163]

[0164]

[0165] Repair promotion rate: Promotion rate = (SM) / (BM)×100%

[0166] S—mean value of tail fin length of fish embryos in the test substance treatment group;

[0167] M—mean value of embryonic tail fin length of fish in the model control group;

[0168] B—The average tail fin length of fish embryos in the blank control group.

[0169] Test 7: In vitro anti-wrinkle and repair efficacy test

[0170] 1. Test basis

[0171] According to the "Detection method of type I collagen (CollagenⅠ) and matrix metalloproteinase 1 (MMP-1) content and NQO-1 gene expression based on fibroblasts", "3D epidermal skin model The detection was carried out according to the "Method for Detecting the Content of Flaggrin (FLG), Loricrin (LOR) and Claudin-1".

[0172] 2. Test Purpose

[0173] This test is divided into three parts: the first part is based on fibroblasts, and cytotoxicity detection is carried out to determine the concentration of the sample on the fibroblasts; the second part uses UVA to irradiate fibroblasts, and evaluates the anti-wrinkle effect of the sample by detecting the changes in the content of type I collagen (CollagenⅠ), matrix metalloproteinase 1 (MMP-1) and NQO-1 gene expression; the third part uses UVB to irradiate the 3D epidermal skin model The repair efficacy of the tested samples was evaluated by detecting the changes in the contents of filaggrin (FLG), loricrin (LOR), and tight junction protein 1 (Claudin-1).

[0174] 3 Test Materials

[0175] 3.1 Test system

[0176] The cells used in this test were fibroblasts, batch number: Fb19052002, provided by Guangdong Boxi Biotechnology Co., Ltd.

[0177] The model used in this test is a 3D epidermal skin model Batch number: ES240405, provided by Guangdong Boxi Biotechnology Co., Ltd.

[0178] 3.2 Sample information

[0179] The ceramide liposome honey recovery provided in Example 1.

[0180] 3.3 Main reagents

[0181] DMEM culture medium (Gibco), EpiGrowth culture medium (Guangdong Boxi Biotechnology), PBS (Solaibao), MTT (Sigma),

[0182] DMSO (Sigma), TGF-β1 (Peprotech), RNAiso Plus (Acori Biotech), reverse transcription kit (Acori Biotech), fluorescent dye (Acori Biotech), Collagen Ι ELISA kit (Cusabio), MMP-1 ELISA kit (Abcam), paraformaldehyde (Biosharp), 4-chloro-6-(2,3-xylyl)-2-pyrimidinethioacetic acid (WY14643) (Sigma), FLG antibody (Abcam), LOR antibody (Abcam), Claudin-1 antibody (Proteintech).

[0183] 3.4 Main Equipment

[0184] CO2 incubator (Thermo, 150I), clean bench (Sujing Antai, SW-CJ-1F), UVA irradiator (Philips), UVB irradiator (Philips), fluorescence microscope (Leica, DM2500), inverted microscope (Olympus, CKX53), ordinary PCR instrument (BioRi, TC-XP-G), fluorescence quantitative PCR instrument (BioRad, CFX-96), and microplate reader (BioTek, Epoch).

[0185] 4.1 Test Method

[0186] 4.1.1 Cell viability test method

[0187] 1) Cell inoculation: After the cells are revived, when the plating rate reaches about 60%, the cells are inoculated into a 96-well plate and incubated overnight in a CO2 incubator (37°C, 5% CO2).

[0188] 2) Experimental grouping: The experiment set up a zero adjustment group, a solvent control group, a positive control group and a sample group. In the sample group, each sample was set with 8 concentration gradients, and 3 replicate wells were set under each concentration gradient.

[0189] 3) Solution preparation: Prepare sample working solutions of different concentrations according to the test concentration setting table (Table 6).

[0190] Table 6

[0191]

[0192] 4) Administration: Administration was performed when the cell plating rate in the 96-well plate reached 50% to 60%. 200 μL of culture medium was added to each well of the solvent control group; 200 μL of culture medium containing 10% DMSO was added to each well of the positive control group; 200 μL of culture medium containing the corresponding concentration of the sample to be tested was added to each well of the sample group; there was no cell inoculation in the zero adjustment group, and only 200 μL of cell culture medium was added. After administration, the 96-well plate was placed in a CO2 incubator (37°C, 5% CO2) for 24 hours.

[0193] 5) Detection: After incubating the cells for 24 hours, discard the supernatant, add MTT working solution (0.5 mg / mL), and incubate at 37°C in the dark for 4 hours. After the incubation, discard the supernatant, add 150 μL DMSO to each well, and read the OD value at 490 nm.

[0194] 6) Calculation of relative cell viability: relative cell viability (%) = (sample well OD -Zero adjustment hole OD ) / (Solvent control wells OD -Zero adjustment hole OD )×100%.

[0195] 4.1.2 Cell morphology test method

[0196] 1) Cell inoculation: After the cells are revived, when the plating rate reaches about 60%, the cells are inoculated into a 24-well plate and incubated overnight in a CO2 incubator (37°C, 5% CO2).

[0197] 2) Experimental grouping: The experiment set up a solvent control group and a sample group. In the sample group, 5 concentration gradients were set for each sample.

[0198] 3) Administration: Administration was performed when the cell plating rate in the 24-well plate reached 50% to 60%. 1 mL of culture medium was added to each well of the solvent control group; 1 mL of culture medium containing the sample of the corresponding concentration was added to each well of the sample group. After administration, the 24-well plate was placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 hours.

[0199] 4) Photography: After incubation, discard the supernatant and take photos under an inverted microscope.

[0200] 4.2 Test Results

[0201] The MTT test results of the sample honey recovery are detailed in Table 7.

[0202] Table 7

[0203]

[0204] See the sample honey recovery cell vitality curve for details. Figure 5 .

[0205] See the sample honey recovery cell morphology for details. Figure 6 .

[0206] Based on the MTT and morphological results, it was considered that the sample honey recovery showed no obvious cytotoxicity based on fibroblasts within the concentration range of 0.00625% (v / v).

[0207] 5 Fibroblast-based tests

[0208] 5.1 Test Method

[0209] 1) Cell inoculation: After the cells are revived, when the plating rate reaches about 60%, the cells are inoculated into a 6-well plate and incubated overnight in a CO2 incubator (37°C, 5% CO2).

[0210] 2) Solution preparation: Prepare the working solution of the test substance according to the test group (Table 8).

[0211] Table 8

[0212]

[0213] Note: PC1 (WY14643) is the positive control of NQO-1, and PC2 (TGF-β1) is the positive control of CollagenⅠ and MMP-1.

[0214] 3) Administration: According to the test grouping, when the cell plating rate in the 6-well plate reaches 30% to 50%, group administration is carried out, and 3 replicate wells are set up for each group. 2 mL of culture medium is added to each well of the blank control group and the negative control group, 2 mL of culture medium containing WY14643 is added to each well of the positive control group 1, 2 mL of culture medium containing TGF-β1 is added to each well of the positive control group 2, and 2 mL of culture medium containing the corresponding concentration of the sample to be tested is added to each well of the sample group. After the administration is completed, the 6-well plate is placed in a CO2 incubator (37°C, 5% CO2) and incubated for 24 hours.

[0215] 4) UVA irradiation: According to the test grouping, except for the blank control group, the remaining groups were irradiated with UVA at a dose of 30 J / cm 2 .

[0216] After irradiation, the cells were placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 h.

[0217] 5) Gene expression detection: After the incubation, discard the old solution, wash twice with PBS, add 1 mL RNAisoPlus to each well, blow and lyse the cells, and collect the samples. Extract RNA, reverse transcribe to cDNA, and perform fluorescence quantitative PCR detection. -△△CT Method to calculate the results.

[0218] 6) ELISA detection: collect the cell culture supernatant and perform detection and analysis according to the operating instructions of the ELISA kit.

[0219] 7) Calculation of increase rate, decrease rate and improvement rate:

[0220] Up-regulation rate (%) = (sample group - negative control group) / negative control group × 100%;

[0221] Down-regulation rate (%) = (negative control group - sample group) / negative control group × 100%;

[0222] Improvement rate (%) = (sample group - negative control group) / negative control group × 100%.

[0223] 8) Statistical analysis of results: GraphPad Prism was used for graphing, and the results were expressed as Mean ± SD. The t-test was used for statistical analysis between the groups. All statistical analyses were two-tailed. P < 0.05 was considered to be significantly different, and P < 0.01 was considered to be extremely significantly different.

[0224] 5.2 Test Results

[0225] 5.2.1 NQO-1 gene test results

[0226] The results of NQO-1 gene testing are shown in Table 9.

[0227] Table 9

[0228]

[0229] Note: Use 2- △△CT Methods The results were calculated and the mRNA amplification times of the BC group were normalized when the t-test method was used for statistical analysis. Compared with the BC group, the significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.

[0230] NQO-1 gene test results are detailed in the bar chart. Figure 7 .

[0231] Compared with the BC group, the NQO-1 gene expression in the NC group was significantly downregulated, indicating that the stimulation conditions in this test were effective.

[0232] Compared with the NC group, the expression of NQO-1 gene in the PC1 group was significantly upregulated, indicating that the positive control in this test was effective.

[0233] Compared with the NC group, the NQO-1 gene expression level in the sample Mi Fu Yuan -0.0125% was significantly upregulated, with an upregulation rate of 72.73%.

[0234] 5.2.2 Type I collagen (Collagen Ⅰ) test results

[0235] The summary table of collagen content test results is shown in Table 10.

[0236] Table 10

[0237]

[0238] Note: When the t-test method was used for statistical analysis, compared with the BC group, the significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.

[0239] Collagen Ι content test results are detailed in the bar graph Figure 8 .

[0240] Compared with the BC group, the Collagen Ι content in the NC group decreased significantly, indicating that the stimulation conditions of this test were effective.

[0241] Compared with the NC group, the Collagen Ι content in the PC2 group increased significantly, indicating that the positive control of this test was effective.

[0242] Compared with the NC group, the Collagen Ι content of the sample Mi Fuyuan-0.0125% was significantly increased, with an increase rate of 61.01%.

[0243] 5.2.3 Matrix metalloproteinase 1 (MMP-1) test results

[0244] The summary table of MMP-1 content detection results is shown in Table 11.

[0245] Table 11

[0246]

[0247] Note: When the t-test method was used for statistical analysis, compared with the BC group, the significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.

[0248] The results of MMP-1 content detection are shown in the bar graph. Fig. 9 .

[0249] Compared with the BC group, the MMP-1 content in the NC group increased significantly, indicating that the stimulation conditions of this test were effective.

[0250] Compared with the NC group, the MMP-1 content in the PC2 group decreased significantly, indicating that the positive control in this test was effective.

[0251] Compared with the NC group, the MMP-1 content of the sample Mi Fu Yuan-0.0125% was significantly decreased, with a downregulation rate of 13.21%. 6 Based on the 3D epidermal skin model Test

[0252] 6.1 Test Method

[0253] 6.1.1 Test Grouping

[0254] The test groups are detailed in Table 12.

[0255] Table 12

[0256]

[0257]

[0258] 6.1.2 Drug administration and irradiation

[0259] 1) According to the test grouping, the model was transferred to a 6-well plate and randomly divided into a blank control group (BC), a negative control group (NC), a positive control group (PC) and a sample group, with 3 replicates in each group.

[0260] 2) Model administration: According to the test groups, 0.9 mL of culture medium was added to each well of the BC group and the NC group, 0.9 mL of culture medium containing WY14643 was added to each well of the PC group, and 0.9 mL of working solution containing the corresponding sample was added to each well of the sample group.

[0261] 3) UVB irradiation: Except for the blank control group, all other groups were irradiated with UVB at a dose of 600 mJ / cm 2 .

[0262] 4) Model incubation: After irradiation, the 6-well plate was placed in a CO2 incubator (37°C, 5% CO2) and incubated for 24 h.

[0263] 5) Cleaning: After the incubation, clean the remaining test substance with sterile PBS solution and wipe off the residual liquid with a sterile cotton swab.

[0264] 6.1.3 Immunofluorescence test

[0265] The model to be tested was fixed with 4% paraformaldehyde for 24 hours, and then immunofluorescence detection was performed. The model was observed and photographed under a microscope, and the images were collected and analyzed.

[0266] 6.1.4 Calculation of promotion rate

[0267] Improvement rate (%) = (sample group - negative control group) / negative control group × 100%.

[0268] 6.1.5 Statistical analysis of results

[0269] GraphPad Prism was used for graphing, and the results were expressed as Mean ± SD. The t-test was used for statistical analysis between the groups. All statistical analyses were two-tailed. P < 0.05 was considered to be significantly different, and P < 0.01 was considered to be extremely significantly different.

[0270] 6.2 Test Results

[0271] 6.2.1 Filaggrin (FLG) test results

[0272] The images were taken with a fluorescence microscope (Leica, DM2500) at a magnification of 20×. The blue fluorescence represents the cell nucleus and the green fluorescence represents FLG. The stronger the green fluorescence intensity, the higher the FLG content. Fig.10 .

[0273] The summary of FLG immunofluorescence analysis results is shown in Table 13.

[0274] Table 13

[0275]

[0276] Note: The integrated optical density (IOD) reflects the content of FLG. When the t-test method was used for statistical analysis, compared with the BC group, the significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.

[0277] FLG relative integrated optical density (IOD) value bar graph, see Fig.11 .

[0278] Compared with the BC group, the FLG content in the NC group decreased significantly, indicating that the stimulation conditions of this test were effective.

[0279] Compared with the NC group, the FLG content in the PC group increased significantly, indicating that the positive control in this test was effective.

[0280] Compared with the NC group, the FLG content of samples Mi Fuyuan-3% and Mi Fuyuan-5% increased significantly, with the increase rates being 128.21% and 194.87%, respectively.

[0281] 6.2.2 Loricrin (LOR) test results

[0282] The images were taken with a fluorescence microscope (Leica, DM2500) at a magnification of 20×. Blue fluorescence represents the cell nucleus, and green fluorescence represents LOR. The stronger the green fluorescence intensity, the higher the LOR content. Fig.12 .

[0283] The summary of LOR immunofluorescence analysis results is shown in Table 14.

[0284] Table 14

[0285] Group Relative IOD average SD P-value BC 1.00 0.06 / NC 0.31 0.02 0.000## PC2 0.59 0.07 0.003** Honey Recovery - 3% 0.26 0.03 0.091 Honey Recovery - 5% 0.30 0.02 0.650

[0286] Note: The value of integrated optical density (IOD) reflects the content of LOR. When the t-test method is used for statistical analysis, compared with the BC group, the significance is indicated by #, P-value < 0.05 is indicated by #, and P-value < 0.01 is indicated by ##; compared with the NC group, the significance is indicated by *, P-value < 0.05 is indicated by *, and P-value < 0.01 is indicated by **.

[0287] For details of the LOR relative integrated optical density (IOD) value bar graph, see Fig.13 .

[0288] Compared with the BC group, the LOR content in the NC group decreased significantly, indicating that the stimulation conditions of this test were effective.

[0289] Compared with the NC group, the LOR content in the PC group increased significantly, indicating that the positive control in this test was effective.

[0290] Compared with the NC group, there was no significant change in the LOR content of samples Mi Fuyuan-3% and Mi Fuyuan-5%.

[0291] 6.2.3 Claudin-1 test results

[0292] The images were taken using a fluorescence microscope (Leica, DM2500) at a magnification of 20×. The blue fluorescence represents the cell nucleus, and the green fluorescence represents Claudin-1. The stronger the green fluorescence intensity, the higher the Claudin-1 content. Fig.14 .

[0293] The summary of Claudin-1 immunofluorescence analysis results is shown in Table 15.

[0294] Table 15

[0295]

[0296] Note: The integrated optical density (IOD) reflects the content of Claudin-1. When the t-test method is used for statistical analysis, compared with the BC group, the significance is indicated by #, P-value < 0.05 is indicated by #, and P-value < 0.01 is indicated by ##; compared with the NC group, the significance is indicated by *, P-value < 0.05 is indicated by *, and P-value < 0.01 is indicated by **.

[0297] For details of the relative integrated optical density (IOD) values ​​of Claudin-1, see Fig.15 .

[0298] Compared with the BC group, the Claudin-1 content in the NC group decreased significantly, indicating that the stimulation conditions of this test were effective.

[0299] Compared with the NC group, the Claudin-1 content in the PC group increased significantly, indicating that the positive control in this test was effective.

[0300] Compared with the NC group, the Claudin-1 content of the samples Mi Fuyuan-3% and Mi Fuyuan-5% increased significantly, with the increase rates being 73.68% and 100.00% respectively.

[0301] 7. Conclusion:

[0302] Anti-wrinkle effect: Based on UVA irradiated fibroblasts, compared with the control group, the content of type I collagen (CollagenⅠ) in the sample Mi Fuyuan at a concentration of 0.0125% (v / v) was significantly increased, with an increase rate of 61.01%, and the content of matrix metalloproteinase 1 (MMP-1) was significantly decreased, with a downregulation rate of 13.21%. The expression of NQO-1 gene was significantly increased, with an upregulation rate of 72.73%. This shows that the sample can increase the content of type I collagen (CollagenⅠ), downregulate the content of matrix metalloproteinase 1 (MMP-1), and upregulate the expression of NQO-1 gene at this concentration, and has an anti-wrinkle effect.

[0303] Repair effect: Based on UVB irradiation 3D epidermal skin model Compared with the control group, the content of FLG and Claudin-1 in the sample Honey Fuyuan at a concentration of 3% (v / v) increased significantly, with an increase rate of 128.21% and 73.68%, respectively, indicating that the sample can increase the content of FLG and Claudin-1 at this concentration, and has a repair effect. The content of FLG and Claudin-1 in the sample Honey Fuyuan at a concentration of 5% (v / v) increased significantly, with an increase rate of 194.87% and 100.00%, respectively, indicating that the sample can increase the content of FLG and Claudin-1 at this concentration, and has a repair effect.

Claims

1. A multifunctional ceramide liposome, characterized in that: The raw materials include, by weight, 0.1-10 parts of effective substances, 1-10 parts of liposomes, 5-20 parts of oils and fats, and 50-100 parts of bases.

2. The multifunctional ceramide liposome according to claim 1, characterized in that: The functional substances include: one or more of ceramide NP, ceramide NH, ceramide AH, ceramide NDS, ceramide AS, ceramide AP, ceramide NS, ceramide EOS, ceramide EOH, ceramide ADS, ceramide EOP, and ceramide EODs.

3. A multifunctional ceramide liposome according to claim 2, characterized in that: The liposome comprises one or more of lecithin, hydrogenated lecithin, cholesterol and phosphatidylcholine.

4. The multifunctional ceramide liposome according to claim 3, characterized in that: The mass ratio of the phosphatidylcholine to cholesterol is (5-20):

1.

5. The multifunctional ceramide liposome according to claim 4, wherein the oil comprises: One or more of octyldodecanol, isododecane and isohexadecane.

6. The multifunctional ceramide liposome according to claim 5, characterized in that: The matrix comprises: deionized water, emulsifier, moisturizer and preservative.

7. The multifunctional ceramide liposome according to claim 6, characterized in that: The emulsifier includes: one or more of anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

8. The multifunctional ceramide liposome according to claim 7, characterized in that: The amphoteric surfactant includes one of sodium dodecylaminopropionate, dodecylethoxysulfobetaine, dodecyldimethylhydroxypropylsulfobetaine, lauroylpropylamine oxide, and sodium di(lauroylamideglutamine)lysine.

9. A method for preparing the multifunctional ceramide liposome according to claim 8, characterized in that: The following steps are involved: S1. Weigh the liposomes, functional substances and oils according to the proportion and stir them at 200-400 rpm in a water bath at 70-95°C to completely dissolve the raw materials to obtain phase A; S2. Deionized water, moisturizer and emulsifier are weighed in proportion, preheated in a water bath at 70-95°C for 30 min, and stirred at 200-350 rpm for 5 min until uniform to obtain phase B. Then, phase A is injected into phase B at a rate of 5 g / min under homogenization conditions at 1000-2000 rpm, and hydration is continued for 20 min. Then, the temperature is lowered to 60-70°C to obtain phase AB. S3, homogenizing the obtained AB phase using a microfluidizer, the homogenization cycle number is 3 times, the first homogenization pressure is set to 20000-25000psi, and the discharge temperature of the first homogenization is controlled to be 50-60°C; the second homogenization pressure is set to 15000-20000psi, and the discharge temperature of the second homogenization is controlled to be 40-50°C; the third homogenization pressure is set to 10000-15000psi, and the discharge temperature of the third homogenization is controlled to be 15-25°C, which is colostrum; S4. After weighing the preservatives according to the proportion, stir at 200-300 rpm until uniform to obtain phase C, add it into the colostrum, continue stirring at 200-400 rpm for 10 minutes until uniform, and then collect the material.

10. A use of the multifunctional ceramide liposome according to claim 8, characterized in that: Used in the field of cosmetics production.

Citation Information

Cited By

  • Glucoside derivative flexible liposome as well as preparation method and application thereof

    CN119235670A

  • A glycoside derivative flexible liposome, its preparation method and application

    CN119235670B

  • Ceramide compound as well as preparation method and application thereof

    CN119857091A

  • Formula system for improving solubility and stability of ceramide NP and preparation method

    CN119868196A

  • A formulation system and preparation method for improving solubility and stability of ceramide NP

    CN119868196B